Transcription factors as targets for cancer therapy
The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
A limited list of transcription factors are overactive in most human cancer cells, which makes them targets for the development of anticancer drugs. That they are the most direct and hopeful targets for treating cancer is proposed, and this is supported by the fact that there are many more human oncogenes in signalling pathways than there are oncogenic transcription factors. But how could specific transcription-factor activity be inhibited?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“STAT3 is a member of a family of seven proteins known to play critical roles in cytokine and growth factor signaling (Darnell, 2002).”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Darnell, 2002
Citations
Cites
1 retracted
Aoki, N., & Matsuda, T. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.1.0761 · Cited by 119
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Notch Signaling: Cell Fate Control and Signal Integration in Development
Artavanis-Tsakonas, S., Rand, M. D., & Lake, R. J. (1999) · Science · doi:10.1126/science.284.5415.770 · Cited by 5,909
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
HOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
STATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201
Dérijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, M., & Davis, R. J. (1994) · Cell · doi:10.1016/0092-8674(94)90380-8 · Cited by 3,188
Cited by
Items 501–600 of 1,001
Structural basis for the binding of high affinity phosphopeptides to Stat3
McMurray, J. S. (2007) · Biopolymers · doi:10.1002/bip.20901 · Cited by 39
GSTP1 negatively regulates Stat3 activation in epidermal growth factor signaling
Kou, X., Chen, N., Feng, Z., Luo, L., & Yin, Z. (2012) · Oncology Letters · doi:10.3892/ol.2012.1098 · Cited by 36
“The signal transducer and activator of transcription (Stat) family of cytoplasmic proteins is important for promoting the proliferation, survival, and other biological processes triggered by cytokines and growth factors, including epidermal growth factor (EGF) (13-15).”
BackgroundYAO, J., DUAN, L., FAN, M., & Wu, X. (2006) · Pharmacological Research · doi:10.1016/j.phrs.2006.08.003 · Cited by 36
Chen, Y., Zhou, C., Li, H., Li, H., & Li, Y. (2020) · Journal of Cancer · doi:10.7150/jca.49392 · Cited by 38
“Dysregulated transcription factor PRKCB could be an appropriate target for the development of anticancer drug [46].”
BackgroundEffects of (5Z)-7-oxozeaenol on the oxidative pathway of cancer cells.
Acuña, U. M., Wittwer, J. A., Ayers, S., Pearce, C. J., Oberlies, N. H., & Blanco, E. J. C. D. (2012) · PubMed · Cited by 34
Unexpected specificity within dynamic transcriptional protein–protein complexes
Henley, M. J., Linhares, B. M., Morgan, B. S., Cierpicki, T., Fierke, C. A., & Mapp, A. K. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2013244117 · Cited by 33
Koganti, S. R. K., de la Paz, A., Freeman, A. F., & Bhaduri‐McIntosh, S. (2013) · Journal of Virology · doi:10.1128/jvi.02601-13 · Cited by 35
Bhargavan, B., Fatma, N., Chhunchha, B., Singh, V., Kubo, E., & Singh, D. P. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.57 · Cited by 38
“The smaller numbers of these transcription factors may be an ideal target for treating/ postponing cancer formation.(29) Thus, we think that LEDGF should be a potential and promising target for development of”
BackgroundAnti-Transcription Factor RNA Aptamers as Potential Therapeutics
Mondragón, E., & Maher, L. J. (2015) · Nucleic Acid Therapeutics · doi:10.1089/nat.2015.0566 · Cited by 35
“While it is commonly recognized that TFs are attractive therapeutic targets for the next generation of drugs, there has been little progress toward this goal [5,6].”
BackgroundTemporary Electrostatic Impairment of DNA Recognition: Light‐Driven DNA Binding of Peptide Dimers
Jiménez‐Balsa, A., Pazos, E., Martínez‐Albardonedo, B., Mascarenas, J. L., & Vázquez, M. E. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201627 · Cited by 34
The pan-cancer pathological regulatory landscape
Falco, M. M., Bleda, M., Carbonell‐Caballero, J., & Dopazo, J. (2016) · Scientific Reports · doi:10.1038/srep39709 · Cited by 40
Transcription factor PU.1 is involved in the progression of glioma
Xu, Y., Gu, S., Bi, Y., Qi, X., Yan, Y., & Lou, M. (2018) · Oncology Letters · doi:10.3892/ol.2018.7766 · Cited by 36
“Abnormal transcriptional programs have been reported playing important roles in the generation and development of malignant carcinoma (1).”
BackgroundDetecting transcription factors with allosteric DNA-Silver nanocluster switches
Li, B., Chen, Y., Wang, J., Lu, Q., Zhu, W., Luo, J., Hong, J., & Zhou, X. (2018) · Analytica Chimica Acta · doi:10.1016/j.aca.2018.10.023 · Cited by 34
Shimada, H., & Ikegaki, N. (2022) · Biomolecules · doi:10.3390/biom12010079 · Cited by 37
“Together, these characteristics make direct targeting of MYC proteins with small molecules a highly formidable task [50].”
BackgroundPatient-level proteomic network prediction by explainable artificial intelligence
Keyl, P., Bockmayr, M. L., Heim, D., Dernbach, G., Montavon, G., Müller, K., & Klauschen, F. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00278-4 · Cited by 44
Qian, X.-J., Li, Y.-T., Yu, Y., Yang, F., Deng, R., Ji, J., Jiao, L., Li, X., Wu, R.-Y., Chen, W.-D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3016 · Cited by 34
“The absence of a clear ligand-binding domain has posed a formidable obstacle toward direct inhibition [34].”
BackgroundFahrmann, J. F., Ballester, O. F., Ballester, G., Witte, T. R., Salazar, A. J., Kordusky, B., Cowen, K. G., Ion, G., Primerano, D. A., Bošković, G., et al. (2012) · Cancer Investigation · doi:10.3109/07357907.2012.743553 · Cited by 34
“Several chromatin conformation related proteins were identified including: JMJD1C [1], which contains histone demethylation protein 2C (40); CHD9 [4] is a chromatin remodeling protein (41, 42); ASH1L [12] is a histone methyl transferase (43); and PKN2 [13] impairs histone deacetylase import (44).”
BackgroundA STAT3 Gene Expression Signature in Gliomas is Associated with a Poor Prognosis
Alvarez, J. V., Mukherjee, N., Chakravarti, A., Robe, P. A. J. T., Zhai, G. G., Chakladar, A., Loeffler, J. S., Black, P. M., & Frank, D. A. (2007) · Translational Oncogenomics · doi:10.4137/tog.s1903 · Cited by 35
Winter, H., Winski, G., Busch, A., Chernogubova, E., Fasolo, F., Wu, Z., Bäcklund, A., Khomtchouk, B. B., Booven, D. J. V., Sachs, N., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.04.020 · Cited by 37
Hou, M., Lu, W.-J., Lin, H.-Y., & Yuann, J. P. (2008) · Biochemistry · doi:10.1021/bi701915f · Cited by 32
Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects
Barton, B. E., & Barton, B. E. (2012) · OncoTargets and Therapy · doi:10.2147/ott.s32559 · Cited by 37
“11,12 For example, signaling by the interleukin 6 (IL-6) family generally induces phosphorylation of STAT3.”
A Central Role for STAT3 in Gammaherpesvirus-Life Cycle and -Diseases
Li, X., & Bhaduri‐McIntosh, S. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01052 · Cited by 33
“Ligation of several cytokine (most notably IL6) receptors and growth factor receptors can activate STAT3; activation typically involves phosphorylation of a tyrosine residue (Y705) (Raz et al., 1994; Schindler and Darnell, 1995; Darnell, 1997, 2002).”
BackgroundA novel statistical approach for identification of the master regulator transcription factor
Sikdar, S., & Datta, S. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1499-x · Cited by 24
“…features of the transcription factors, in addition to the facts that they are much smaller in number than the oncogenes and have well-regulated expression and activities, transcription factors are gaining popularity as potential therapeutic targets in anti-cancer drug development [3, 4, 7, 8].”
BackgroundInhibition of IL-6/STAT3 signaling in human cancer cells using Evista
Shi, W., Yan, D., Zhao, C., Xiao, M., Wang, Y., Ma, H., Liu, T., Qin, H., Zhang, C., Li, C., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.07.067 · Cited by 33
Qi, F., Qin, W., & Zang, Y. (2019) · Oncology Letters · doi:10.3892/ol.2019.9884 · Cited by 32
Protein‐Controlled Actuation of Dynamic Nucleic Acid Networks by Using Synthetic DNA Translators**
Bertucci, A., Porchetta, A., Grosso, E. D., Patiño, T., Idili, A., & Ricci, F. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202008553 · Cited by 34
Gao, D., Jin, N., Fu, Y., Zhu, Y., Wang, Y., Wang, T., Chen, Y., Zhang, M., Xiao, Q., Huang, M., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113333 · Cited by 32
Sferra (2011) · Molecular Medicine Reports · doi:10.3892/mmr.2011.413 · Cited by 34
Heffern, M. C., Kurutz, J. W., & Meade, T. J. (2013) · Chemistry - A European Journal · doi:10.1002/chem.201301659 · Cited by 37
Zannetti, A., Vecchio, S. D., Romanelli, A., Scala, S., Saviano, M., Calı̀, G., Stoppelli, M. P., Pedone, C., & Salvatore, M. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.07.024 · Cited by 32
Sequence- and structural-selective nucleic acid binding revealed by the melting of mixtures
Shi, X. (2006) · Nucleic Acids Research · doi:10.1093/nar/gnj012 · Cited by 32
Effects of super-enhancers in cancer metastasis: mechanisms and therapeutic targets
Liu, S., Dai, W., Jin, B., Jiang, F., Huang, H., Hou, W., Lan, J., Jin, Y., Peng, W., & Pan, J. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02033-8 · Cited by 41
“Nevertheless, due to structural heterogeneity and the absence of accessible active sites, these proteins have been deemed undruggable, resulting in only a handful of them being effectively targeted by conventional small molecules [200].”
BackgroundHeng, L., Jia, Z., Bai, J., Zhang, K., Zhu, Y., Ma, J., Zhang, J., & Duan, H. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6286 · Cited by 32
“Transcription factors (TFs) ( 9) and microRNAs (miRNAs) (10) are the two critical regulators targeting protein-coding genes involved in cancer initiation and progression.”
TCF4 promotes colorectal cancer drug resistance and stemness via regulating ZEB1/ZEB2 expression
Sun, S., Yang, X., Qin, X., & Zhao, Y. (2020) · PROTOPLASMA · doi:10.1007/s00709-020-01480-6 · Cited by 36
Parajuli, P., Tiwari, R., & Sylvester, P. W. (2015) · Cell Proliferation · doi:10.1111/cpr.12196 · Cited by 33
Protein–protein interactions in transcription: A fertile ground for helix mimetics
Guarracino, D. A., Bullock, B. N., & Arora, P. S. (2010) · Biopolymers · doi:10.1002/bip.21546 · Cited by 38
SPARC expression induces cell cycle arrest via STAT3 signaling pathway in medulloblastoma cells
Chetty, C., Dontula, R., Nagaraju, G. P., Gujrati, M., & Lakka, S. S. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.12.065 · Cited by 31
Willis, R. E. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091552 · Cited by 41
“He proposed that they are the most direct and hopeful targets for treating cancer [162].”
BackgroundDhingra, P., Martinez‐Fundichely, A., Berger, A., Huang, F. W., Forbes, A. N., Liu, E. M., Liu, D., Sboner, A., Tamayo, P., Rickman, D. S., et al. (2017) · Genome biology · doi:10.1186/s13059-017-1266-3 · Cited by 30
Signal transducer and activator of transcription signals in allergic disease
Chen, W., & Hershey, G. K. K. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.01.004 · Cited by 36
“Unlike STAT1, the C-terminal region of STAT3 (amino acids 321-771) contains the nuclear export activity, whereas the N-terminal part (1-320) has the nuclear localization signal.”
Systems biology of JAK/STAT signalling
Pfeifer, A. C., Timmer, J., & Klingmüller, U. (2008) · Essays in Biochemistry · doi:10.1042/bse0450109 · Cited by 42
SOX on tumors, a comfort or a constraint?
Jiang, J., Wang, Y., Sun, M., Luo, X., Zhang, Z., Wang, Y., Li, S., Hu, D. X., Zhang, J., Wu, Z., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01834-6 · Cited by 32
“Of all protooncogenes, approximately 19% are transcription factors [2].”
BackgroundBreunig, C., Erdem, N., Bott, A., Greiwe, J. F., Reinz, E., Bernhardt, S., Giacomelli, C., Wachter, A., Kanthelhardt, E. J., Beißbarth, T., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12355 · Cited by 32
Identification of HMGA2 inhibitors by AlphaScreen-based ultra-high-throughput screening assays
Su, L., Bryan, N., Battista, S., de Freitas, J. T., Garabedian, A., D’Alessio, F., Romano, M., Falanga, F., Fusco, A., Kos, L., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-75890-0 · Cited by 32
Chen, X., Gao, F., Yang, W., Sun, J., Zhou, Z., & Ji, L. (2011) · Inorganica Chimica Acta · doi:10.1016/j.ica.2011.08.047 · Cited by 30
Pectenotoxin-2 from Marine Sponges: A Potential Anti-Cancer Agent—A Review
Kim, G., Kim, W., & Choi, Y. H. (2011) · Marine Drugs · doi:10.3390/md9112176 · Cited by 31
“Among them, NF-κB plays a key role in cellular signal transduction systems by regulating the immune response to infection [24].”
Cai, T., Wagenlehner, F. R. A., Mazzoli, S., Meacci, F., Mondaini, N., Nesi, G., TISCIONE, D., MALOSSINI, G., & Bartoletti, R. (2012) · Journal of Andrology · doi:10.2164/jandrol.111.013961 · Cited by 30
Zhang, C., Su, Z., Wang, L., Shu, L., Yang, Y., Guo, Y., Pung, D., Bountra, C., & Kong, A. T. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.08.009 · Cited by 36
Xu, Z., Pei, C., Cheng, H., Song, K., Yang, J., Li, Y., He, Y., Liang, W., Liu, B., Tan, W., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1138524 · Cited by 31
“The strategy of targeting transcription factors has been considered a promising approach in tumor therapy (7).”
BackgroundMultiple spatially related pharmacophores define small molecule inhibitors of OLIG2 in glioblastoma
Tsigelny, I. F., Mukthavaram, R., Kouznetsova, V. L., Chao, Y. S., Babić, I., Nurmemmedov, E., Pastorino, S., Jiang, P., Calligaris, D., Agar, N. Y. R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5633 · Cited by 30
“Hence TFs may represent an important therapeutic target [6-9].”
BackgroundTopological patterns in microRNA–gene regulatory network: studies in colorectal and breast cancer
Sengupta, D., & Bandyopadhyay, S. (2013) · Molecular BioSystems · doi:10.1039/c3mb25518b · Cited by 30
The (pro)renin receptor ((P)RR) can act as a repressor of Wnt signalling
Bernhard, S., Seidel, K., Schmitz, J., Klare, S., Kirsch, S., Schrezenmeier, E. V., Zaade, D., Meýborg, H., Goldin-Lang, P., Stawowy, P., et al. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.09.020 · Cited by 29
Dynamic, Large-Scale Profiling of Transcription Factor Activity from Live Cells in 3D Culture
Weiss, M. S., Bernabé, B. P., Bellis, A. D., Broadbelt, L. J., Jeruss, J. S., & Shea, L. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014026 · Cited by 29
“HIF1, IRF1, ISRE, NFkB, p53, and SP1 had activities that increased with time and CRE, RAR, and SRF had activities that decreased with time (Fig.”
BackgroundIn silico analysis of differential gene expressions in biliary stricture and hepatic carcinoma
Gupta, M. K., Behera, S. K., & Vadde, R. (2016) · Gene · doi:10.1016/j.gene.2016.10.032 · Cited by 32
Corcoran, D. B., Lewis, T., Nahar, K. S., Jamshidi, S., Fegan, C., Pepper, C. J., Thurston, D. E., & Rahman, K. M. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01849 · Cited by 28
Expression profile and prognostic values of STAT family members in non-small cell lung cancer.
Yang, M., Chen, H., Zhou, L., Chen, K., & Su, F. (2019) · Europe PMC (PubMed Central) · Cited by 35
Feng, K.-R., Wang, F., Shi, X., Tan, Y., Zhao, J., Zhang, J., Li, Q., Lin, G., Gao, D., & Tian, P. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112428 · Cited by 29
Bhat, R. R., Thangavel, H., Abdulkareem, N. M., Vasaikar, S. V., Angelis, C. D., Bae, L., Cataldo, M. L., Nanda, S., Fu, X., Zhang, B., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-05949-7 · Cited by 36
Liu, A., Liu, Y., Jin, Z., Hu, Q., Li, L., Jou, D., Yang, J., Xu, Z., Wang, H., Li, C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046624 · Cited by 33
“Selectively targeting activated STAT3 signaling has been shown to be effective in inhibiting cancerassociated processes and cancer cell viability [26,27].”
Small-molecule regulators that mimic transcription factors
Rodríguez‐Martínez, J. A., Peterson‐Kaufman, K. J., & Ansari, A. Z. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.08.010 · Cited by 29
Zhang, X., Blaskovich, M. A., Forinash, K. D., & Sebti, S. M. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.349 · Cited by 30
Mughal, T. I., Girnius, S. K., Rosen, S. T., Kumar, S. K., Wiestner, A. U., Abdel-Wahab, O. I., Kiladjian, J., Wilson, W. H., & Etten, R. A. V. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.863307 · Cited by 30
Achcar, R. D., Cagle, P. T., & Jagirdar, J. S. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-1350-eoaals · Cited by 30
Acuña, U. M., Carcache, P. J. B., Matthew, S., & de Blanco, E. J. C. (2016) · Food Chemistry · doi:10.1016/j.foodchem.2016.01.060 · Cited by 29
“Thus, NF-κB inhibition triggers apoptosis in cancer cells and induces apoptosis selectively in cancer cells (Darnell, 2002).”
BackgroundBernadó, P., Pérez, Y., Blobel, J., Fernández‐Recio, J., Svergun, D. I., & Pons, M. (2009) · Protein Science · doi:10.1002/pro.83 · Cited by 33
“phosphorylated STAT activity are associated with cancer.(10,11) Seven mammalian STAT genes have been identified both in human and mouse genomes, Stat1, Stat2,”
BackgroundHsieh, T., Liu, T., Lu, F., Hsieh, P.-Y., & Chen, C. (2005) · Food and Chemical Toxicology · doi:10.1016/j.fct.2005.08.005 · Cited by 32
Temperature-sensitive protein–DNA dimerizers
Hauschild, K. E., Metzler, R. E., Arndt, H., Moretti, R., Raffaelle, M., Dervan, P. B., & Ansari, A. Z. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501289102 · Cited by 29
Shelake, S., Sankpal, U. T., Bowman, W. P., Wise, M., Ray, A., & Basha, R. M. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0417-9 · Cited by 28
Vázquez, O., Vázquez, M. E., Blanco‐Canosa, J. B., Castedo, L., & Mascarenas, J. L. (2007) · Angewandte Chemie · doi:10.1002/ange.200702345 · Cited by 28
Tpl2 Inhibitors Thwart Endothelial Cell Function in Angiogenesis and Peritoneal Dissemination
Lee, W., Lan, K., Chou, C., Yi, Y., Chen, W.-C., Pan, H.-C., Peng, Y., Wang, K.-B., Chen, Y.-C., Chao, T., et al. (2013) · Neoplasia · doi:10.1593/neo.121914 · Cited by 30
“Emerging evidence shows that transcription factors are activated by phosphorylation and then translocated to the nucleolus that subsequently regulates angiogenesis [24].”
BackgroundChen, X., Gao, F., Yang, W., Zhou, Z., Lin, J., & Ji, L. (2013) · Chemistry & Biodiversity · doi:10.1002/cbdv.201100414 · Cited by 28
Viger, A., & Dervan, P. B. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.08.028 · Cited by 28
Mandal, P. K., Heard, P. A., Ren, Z., Chen, X., & McMurray, J. S. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.10.099 · Cited by 28
Bonham, A. J., Neumann, T., Tirrell, M., & Reich, N. O. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp424 · Cited by 27
“Transcriptional regulation is an essential gatekeeper in carcinogenesis ( 1 ), defining tissue and species identity, maintenance of cell function and cis-regulatory evolution (2).”
BackgroundSamanta, A. K., Huang, H. J., Le, X., Mao, W., Lu, K. H., Bast, R. C., & Liao, W. S. ‐. (2009) · Cancer · doi:10.1002/cncr.24445 · Cited by 28
“The IKK kinase reaction was initiated by the addition of kinase buffer containing 20 lM ATP, 10 lCi (c-32P)ATP, and 1 lg GST-IjBa(1-54) and incubated at 30 C for 20 minutes.”
MethodInfluentialLis, C., Rubner, S., Roatsch, M., Berg, A., Gilcrest, T., Fu, D., Nguyen, E. D., Schmidt, A.-M., Krautscheid, H., Meiler, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17600-x · Cited by 30
“Apparent IC50-values of the ethyl (6)22, isopropyl (7), and tert-butyl (8) derivatives No Structure STAT1 app.”
Dichotomies in cancer research: some suggestions for a new synthesis
Sporn, M. B. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0536 · Cited by 32
The sequence–structure–function relationship of intrinsic ERα disorder
Du, Z., Wang, H., Luo, S., Yun, Z., Wu, C., Yang, W., Buck, M., Zheng, W., Hansen, A. L., Kao, H., et al. (2025) · Nature · doi:10.1038/s41586-024-08400-1 · Cited by 32
A Notch above other inhibitors
Arora, P. S., & Ansari, A. Z. (2009) · Nature · doi:10.1038/462171a · Cited by 28
Cooperative interactions between p53 and NFκB enhance cell plasticity
Bisio, A., Zámborszky, J., Zaccara, S., Lion, M., Tebaldi, T., Sharma, V., Raimondi, I., Alessandrini, F., Ciribilli, Y., & Inga, A. (2014) · Oncotarget · doi:10.18632/oncotarget.2545 · Cited by 32
“Cellular responses to changes in the microenvironment requires coordinated activation of sequence-specific transcription factors [6], among which NFκB and p53 have a prominent role and often opposing functions [7].”
Noman, M. A. A., Hossain, T., Ahsan, M., Jamshidi, S., Hasan, C. M., & Rahman, K. M. (2018) · Journal of Natural Products · doi:10.1021/acs.jnatprod.7b00377 · Cited by 30
Ren, S., Xing, Y., Wang, C., Jiang, F., Liu, G., Li, Z., Jiang, T., Zhu, Y., & Piao, D. (2020) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105777 · Cited by 30
Genomics and Functional Genomics of Malignant Pleural Mesothelioma
Çakıroğlu, E., & Şentürk, Ş. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176342 · Cited by 31
Molecular Mechanisms of Cancer Prevention by Gooseberry ( Phyllanthus emblica )
Kumar, G., Madka, V., Pathuri, G., Ganta, V., & Rao, C. V. (2021) · Nutrition and Cancer · doi:10.1080/01635581.2021.2008988 · Cited by 27
“Activation of transcription factors is required for the survival, unrestrained growth, and metastatic development of all cancers (43).”
BackgroundSerpin B3/B4, activated by STAT3, promote survival of squamous carcinoma cells
Ahmed, S. T., & Darnell, J. E., Jr. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.11.147 · Cited by 30
Mistry, I. N., & Tavassoli, A. (2016) · ACS Synthetic Biology · doi:10.1021/acssynbio.6b00219 · Cited by 28
“intervention, but transcription factors are considered to be one of the most chemically 38 intractable targets in drug discovery.(1) More generally, the challenge of identifying PPI 39”
Robust Causal Structure Learning with Some Hidden Variables
Frot, B., Nandy, P., & Maathuis, M. H. (2019) · Journal of the Royal Statistical Society Series B (Statistical Methodology) · doi:10.1111/rssb.12315 · Cited by 60
“Transcription factors play a crucial role in cancer development, which is why it is believed that intervening on the expression of such genes could alter the course of some cancers (Darnell, 2002).”
BackgroundInhibition of AP-1 and MAPK signaling and activation of Nrf2/ARE pathway by quercitrin
Ding (2009) · International Journal of Oncology · doi:10.3892/ijo_00000475 · Cited by 89
Involvement of c-Src/STAT3 signal in EGF-induced proliferation of rat spermatogonial stem cells
Chen, J., Xu, L., Wang, X.-C., Qin, H.-Y., & Wang, J. (2011) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-0922-2 · Cited by 27
Oncogenes as molecular targets in lymphoma
Hachem, A., & Gartenhaus, R. B. (2005) · Blood · doi:10.1182/blood-2004-12-4621 · Cited by 39
Ji, P., Xu, X., Ma, S., Fan, J., Zhou, Q., Mao, X., & Qiao, C. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00228 · Cited by 30
Endogenous Inhibitors of Nuclear Factor-κB, An Opportunity for Cancer Control
Chen, F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2096 · Cited by 30
“However, a number of nongenetic factors, such as the regulation of gene expression, post-transcriptional modification, and the kinasebased signal transduction, cannot be ignored (2).”
BackgroundTranscription Factors and Cancer: Approaches to Targeting
Shiah, J. V., Johnson, D. E., & Grandis, J. R. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000639 · Cited by 29
“As gain-of-function oncogenes, for which they comprise approximately 20% of those currently identified, transcription factors drive constitutive signaling of proliferation pathways, whereas as tumor suppressors, their loss of function or deletion contributes to evasion of cell death mechanisms, both of which are quint…”
BackgroundRole of Fos‐related antigen 1 in the progression and prognosis of ductal breast carcinoma
Logullo, Â. F., Stiepcich, M. M., Osório, C. A. B. D. T., Nonogaki, S., Pasini, F. S., Rocha, R. M., Soares, F. A., & Brentani, M. M. (2011) · Histopathology · doi:10.1111/j.1365-2559.2011.03785.x · Cited by 27
“All of these properties are hypothesized to depend on deregulated transcription.(1) The transcription activator protein, activator protein 1 (AP-1), has been broadly implicated in tumour progression, and many genes involved in cell proliferation, differentiation, malignant transformation and cell invasion are AP-1-dep…”
BackgroundSignatures of DNA target selectivity by ETS transcription factors
Poon, G. M. K., & Kim, H. M. (2017) · Transcription · doi:10.1080/21541264.2017.1302901 · Cited by 30
Zhang, Y., Xiang, D., Tang, B., & Zhang, C. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b02451 · Cited by 27
WSB1 regulates c-Myc expression through β-catenin signaling and forms a feedforward circuit
Gao, X., You, J., Gong, Y., Meng, Y. G., Zhu, H., Fang, L., Zhu, H., Ying, M., He, Q., Yang, B., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.10.021 · Cited by 35
Immunotherapy as part of a multidisciplinary approach to melanoma treatment
Adam, I. R. (2006) · Frontiers in bioscience · doi:10.2741/1775 · Cited by 28
Kim, M.-O., Moon, D., Heo, M., Lee, J.-D., Jung, J. H., Kim, S., Choi, Y. H., & Kim, G. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.05.034 · Cited by 26
Bigelovin inhibits STAT3 signaling by inactivating JAK2 and induces apoptosis in human cancer cells
Zhang, H., Kuang, S., Wang, Y., Sun, X., Gu, Y. J., Hu, L., & Yu, Q. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.143 · Cited by 26
Metadata
- Authors
- Darnell, J. E.
- Venue
- Nature Reviews Cancer
- Published
- 2002-10
- Volume
- 2
- Issue
- 10
- Pages
- 740-749
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1980480652
- Cited by
- 1,194
- References
- 109
- Citations by year
- 2026: 29 · 2025: 37 · 2024: 41 · 2023: 48 · 2022: 37 · 2021: 45 · 2020: 48 · 2019: 48 · 2018: 47 · 2017: 64 · 2016: 50 · 2015: 77 · 2014: 76 · 2013: 87 · 2012: 73
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- transcription factors, cancer therapy, anticancer drug targets, oncogenes, oncogenic transcription factor, signaling pathways, transcription factor inhibition
- MeSH terms
- Antineoplastic Agents, Cytoplasm, Cytoskeletal Proteins, Humans, Ligands, Models, Biological, Mutation, Neoplasms, Protein Binding, Proto-Oncogene Proteins, Transcription Factors, Transcription, Genetic, Signal Transduction, Trans-Activators, NF-kappa B, Apoptosis, Zebrafish Proteins, Wnt Proteins, beta Catenin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.